Halozyme Therapeutics (NASDAQ: HALO) has pulled its proposal to buy Evotec SE (NASDAQ: EVO) for 2 billion euros ($2.09 billion) […]
Halozyme Withdraws $2.1 Billion Acquisition Bid for Evotec Read More »
On Thursday, Halozyme Therapeutics (NASDAQ: HALO) said it has proposed to buy German drug developer Evotec (NASDAQ: EVO) for about
Evotec Receives €2 Billion Buyout Offer from Halozyme Therapeutics Read More »
Shares in Evotec (NASDAQ: EVO) soared 22% on Monday after private equity firm Triton confirmed a close to 10% stake
Evotec (NASDAQ: EVO), the German drug and development company, has entered into a technology development partnership with Novo Nordisk (NYSE:
Copyright © 2024 abbonews.com
